Co-Diagnostics, Inc. filings document a molecular diagnostics company’s operating results, material events, governance actions, and capital-structure disclosures. Recent 8-K filings cover financial results, Regulation FD disclosures, non-GAAP presentation references, Nasdaq listing-rule matters, and other corporate events tied to the company’s common stock.
Proxy and material-event filings also describe shareholder voting matters, including authorization for a reverse stock split, along with governance procedures and security-structure changes. The filing record links the company’s Co-Dx PCR platform, clinical and regulatory disclosures, commercialization activities, and public-company reporting obligations with risk, liquidity, listing, and ownership-related disclosure categories.
Co-Diagnostics, Inc. adjourned its annual meeting after it failed to achieve a quorum on September 3 and again on September 24, 2026. The reconvened meeting is scheduled for September 30, 2026, at 9:00 a.m. Mountain Time at the company’s offices in Salt Lake City. Stockholders will vote as described in the definitive proxy statement, and valid proxies submitted before the reconvened meeting remain effective unless properly changed or revoked before votes are taken.
Co-Diagnostics, Inc. (CODX) is calling a special stockholder meeting in 2026 to vote on three items: approval of the potential exercise of new common stock warrants, authorization of a reverse stock split, and approval of possible adjournments of the meeting to secure sufficient votes.
The company seeks approval for the issuance of up to 3,404,724 shares of common stock upon exercise of new warrants with a $1.56 per share exercise price. If fully exercised for cash, these New Warrants could provide up to $5.31 million in gross proceeds; they are currently not exercisable without stockholder approval under Nasdaq Listing Rule 5635(d). After the Warrant Inducement transaction, shares outstanding were 6,980,208, so full warrant exercise would cause meaningful dilution.
The Board also requests authority to implement, within twelve months, a reverse stock split of outstanding common stock at any ratio between 1‑for‑2 and 1‑for‑50, without changing the 100,000,000 authorized common shares. The company states the main goals are supporting continued Nasdaq listing and improving the trading price, while noting risks such as potential reduced liquidity and an anti-takeover effect from more authorized but unissued shares.
Co-Diagnostics, Inc. (CODX) reports that on September 16, 2026 it will host an investor and analyst presentation. The presentation will cover the company’s collaboration with ReadyGo Diagnostics Ltd., its Co-Dx PCR platform and related development activities, manufacturing initiatives, and operations in India.
The slide deck for this event is provided as an Investor and Analyst Presentation dated September 16, 2026 and furnished as Exhibit 99.1 under a Regulation FD disclosure, meaning it is supplied for informational purposes and is not treated as filed under the Exchange Act.
Co-Diagnostics, Inc. (CODX) reported a new collaboration with ReadyGo Diagnostics Ltd. to evaluate using ReadyGo’s GoCollect® blood sample-preparation technology with the Co-Dx® PCR platform for blood-based molecular testing at the point of need, initially focused on decentralized Ebola virus detection and outbreak response.
The companies have begun feasibility work to assess workflow compatibility, building on Co-Diagnostics’ earlier Ebola plasma proof-of-concept. Success could extend the Co-Dx PCR platform beyond swab-based testing into bloodborne pathogens such as HIV and hepatitis B and C, though each application would require separate development, validation, and regulatory authorization and there is no assurance of a commercial product.
Co-Diagnostics, Inc. (CODX) reported that in August 2026 it entered into a material transfer agreement with ReadyGo Diagnostics Ltd to evaluate the compatibility of ReadyGo’s sample collection and preparation technologies with the Co-Dx PCR platform. ReadyGo will supply sampling materials for feasibility, evaluation and compatibility testing.
The company believes ReadyGo’s technologies may complement the Co-Dx PCR platform’s goal of enabling real-time PCR testing in decentralized and point-of-care settings by simplifying sample collection, stabilization and preparation. The evaluation is preliminary, does not obligate either party to any development, supply or commercialization agreement, and may not result in any further relationship. The Co-Dx PCR platform and associated tests remain subject to regulatory review and are not currently available for sale.
Co-Diagnostics, Inc. (CODX) reported an initial ownership statement for Daniel Bohrer, EVP of Finance & Accounting, showing direct ownership of 3,657 shares of common stock as of the reporting date. This amount includes 2,722 unvested restricted stock units (RSUs) granted under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan.
The unvested RSUs comprise 2,500 RSUs awarded on April 26, 2024 and 2,834 RSUs awarded on August 11, 2025, of which 1,667 and 945, respectively, had previously vested. The April 26, 2024 award vests in equal amounts every six months from November 23, 2024 through May 23, 2027, and the August 11, 2025 award vests in equal amounts every six months from November 23, 2025 through May 23, 2028. No Rule 10b5-1 trading plan is reported.
Co-Diagnostics, Inc. (CODX) reported that Chief Financial Officer Brian Brown’s employment ended on September 2, 2026, which was his last day serving as the company’s principal financial officer and principal accounting officer. On the same date, Daniel Bohrer, Executive Vice President of Finance and Accounting, was designated as the new principal financial officer and principal accounting officer.
In connection with this appointment, Mr. Bohrer’s annual salary increased from $225,000 to $255,000. The company notes that Mr. Bohrer, age 49, has extensive prior experience in finance, accounting, and audit roles at Co-Diagnostics, Workfront, Inc., and EY, and that he has no family relationships, related person transactions, or selection arrangements with other company insiders.
Co-Diagnostics, Inc. (CODX) reported that its September 3, 2026 Annual Meeting of Stockholders did not achieve a quorum, so no business could be conducted. Under the company’s bylaws, the chairperson adjourned the meeting.
The Annual Meeting is adjourned to September 24, 2026 at 9:00 a.m. Mountain Time, to be held at the company’s offices at 2401 S. Foothill Dr, Ste. D, Salt Lake City, Utah 84109. Stockholders may participate and vote as described in the definitive proxy statement filed on July 21, 2026, and all valid proxies already submitted will remain effective for the reconvened meeting unless changed or revoked before votes are taken.
Co-Diagnostics, Inc. (CODX) is registering the resale of up to 3,404,724 shares of common stock for selling stockholders. These shares are issuable upon exercise of “New Warrants” issued under a July 30, 2026 Inducement Letter. CODX will not receive proceeds from the selling stockholders’ resales.
If all New Warrants are exercised for cash at $1.56 per share, CODX could receive up to approximately $5.31 million, planned for working capital and general corporate purposes; the warrants are also exercisable on a cashless basis, in which case the company would receive no cash. Common shares outstanding were 6,981,319 as of August 20, 2026, or 10,386,043 assuming full exercise of the New Warrants.
CODX develops and sells PCR-based molecular diagnostics, including tests for COVID‑19 and other infectious diseases, and is pursuing U.S. FDA clearance for its Co-Dx PCR platform. The company highlights dilution and stock overhang risks from warrant exercises and future equity issuances, and notes Nasdaq listing under the symbol CODX.